Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steve Fancy who wrote (3854)	2/19/1998 5:03:00 PM
From: Peter Singleton	of 6136

Steve, thanks for posting the PW update. Two numbers to keep our eyes on would be the Norvir scrip # (as EW points out, giving an indication of Norvir + saquinavir hgc/sgc prescriptions), and especially the combined number for Roche's Invirase and Fortovase. Viracept has been edging up in market share about a point a month. If Fortovase takes off, Viracept's market share growth may stall. It's hard to tell from the data so far. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next